Age Related Vision Dysfunction Market: High-Growth Opportunities for Investors to 2034 - DelveInsight

DelveInsight's "Age Related Vision Dysfunction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Age Related Vision Dysfunction, historical and forecasted epidemiology as well as the Age Related Vision Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Age Related Vision Dysfunction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Age Related Vision Dysfunction Market Forecast
https://www.delveinsight.com/sample-request/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=promotion&utm_campaign=gpr

Some of the key facts of the Age Related Vision Dysfunction Market Report:
• The Age Related Vision Dysfunction market size was valued approximately USD 54 Billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In March 2025, Luxa Biotechnology LLC (Luxa), a clinical-stage biotech firm focused on developing an innovative adult retinal pigment epithelial stem cell (RPESC) therapy for dry age-related macular degeneration (AMD), has announced clinical results from its Phase 1/2a trial. The study is assessing RPESC-RPE-4W, the company's proprietary retinal pigment epithelium (RPE) cell therapy, in patients with dry AMD.
• In December 2024, Galimedix Therapeutics has launched its Phase II eDREAM clinical trial to evaluate the safety and effectiveness of GAL-101 eye drops in individuals with dry age-related macular degeneration.
• In December 2024, Ocugen, Inc. reported that the Data and Safety Monitoring Board (DSMB) overseeing the OCU410 ArMaDa clinical trial has met and granted approval to proceed with the second part of the Phase 1/2 study. OCU410 (AAV5-hRORA) is an innovative modifier gene therapy being developed to treat geographic atrophy (GA) associated with dry age-related macular degeneration (dAMD).
• In November 2024, Ocugen, Inc. shared encouraging initial efficacy and safety results from the Phase I dose-escalation segment of its Phase 1/2 OCU410 ArMaDa clinical trial targeting geographic atrophy (GA) linked to dry age-related macular degeneration (dAMD). Highlights include the absence of drug-related serious adverse events, slower lesion progression, preservation of retinal tissue, and notably, a positive impact on low luminance visual acuity (LLVA), a key functional vision metric.
• In February 2024, Outlook Therapeutics stated that the resubmission of the ONS-5010 Biologics License Application (BLA) is anticipated by the end of the 2024 calendar year. Additionally, in March 2024, the company announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion regarding the approval of ONS-5010/LYTENAVA for the treatment of wet age-related macular degeneration in the EU.
• KSI-301, ONS-5010 / LYTENAVA, and EYP-1901 are among the most anticipated emerging therapies/products pending approval and are expected to drive growth in the Age-related Vision Dysfunction market.
• In the 7MM, there were about 7,322,693 glaucoma cases per year in 2022. Throughout the predicted era (2024-2034), it is anticipated that these cases will rise
• In the 7MM, there were roughly 52,684,884 instances of Wet-AMD in 2022. 35% of these cases originated in the United States
• By 2022, there will be about 293,229,468 cases of presbyopia in the 7MM. By 2034, there will likely be an increase in these cases, which are now on the rise
• In the year 2022, the US had an estimated 5,116,551 prevalent instances of glaucoma, while Spain had 947,500 cases
• In 2022, the UK had the highest prevalence of Wet-AMD cases among the European nations, and this number is projected to rise in the next years
• Key Age Related Vision Dysfunction Companies: Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals, and others
• Key Age Related Vision Dysfunction Therapies: KSI-301, ONS-5010, LYTENAVA, EYP-1901, and others
• The Age Related Vision Dysfunction epidemiology based on type specific cases analyzed that the cases of presbyopia are the highest among all the considered etiologies of in the 7MM
• The Age Related Vision Dysfunction market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Age Related Vision Dysfunction pipeline products will significantly revolutionize the Age Related Vision Dysfunction market dynamics.

Age Related Vision Dysfunction Overview
The macula, a little area at the centre of the retina that is in charge of sharp central vision, is the primary area of the retina that is affected by age-related macular degeneration. There are two forms of AMD: dry and moist. Every type demands a distinct strategy to treatment.

Get a Free sample for the Age Related Vision Dysfunction Market Report:
https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=promotion&utm_campaign=gpr

Age Related Vision Dysfunction Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Age Related Vision Dysfunction Epidemiology Segmentation:
The Age Related Vision Dysfunction market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Age Related Vision Dysfunction
• Prevalent Cases of Age Related Vision Dysfunction by severity
• Gender-specific Prevalence of Age Related Vision Dysfunction
• Diagnosed Cases of Episodic and Chronic Age Related Vision Dysfunction

Download the report to understand which factors are driving Age Related Vision Dysfunction epidemiology trends @ Age Related Vision Dysfunction Epidemiology Forecast
https://www.delveinsight.com/sample-request/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=promotion&utm_campaign=gpr

Age Related Vision Dysfunction Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Age Related Vision Dysfunction market or expected to get launched during the study period. The analysis covers Age Related Vision Dysfunction market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Age Related Vision Dysfunction Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Age Related Vision Dysfunction Therapies and Key Companies
• KSI-301: Kodiak Sciences Inc.
• ONS-5010 / LYTENAVA: Outlook Therapeutics
• EYP-1901: Eye point Pharmaceuticals

Discover more about therapies set to grab major Age Related Vision Dysfunction market share @ Age Related Vision Dysfunction Treatment Market
https://www.delveinsight.com/sample-request/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=promotion&utm_campaign=gpr

Age Related Vision Dysfunction Market Strengths
• Label expansion into other kinds of indications is also very much on the cards if the drug approved in one indications is able to show a similar kind of efficacy. E.g. Eylea was first approved by the FDA for Wet Age-Related Macular Degeneration and later the label was expanded for Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Age Related Vision Dysfunction Market Opportunities
• In indications like presbyopia and cataract, there are limited pharmacologically approved treatment, and physicians and patients are still waiting for safe and effective treatment options for this huge patient pool

Scope of the Age Related Vision Dysfunction Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Age Related Vision Dysfunction Companies: Kodiak Sciences Inc., Outlook Therapeutics, Eye point Pharmaceuticals, and others
• Key Age Related Vision Dysfunction Therapies: KSI-301, ONS-5010, LYTENAVA, EYP-1901, and others
• Age Related Vision Dysfunction Therapeutic Assessment: Age Related Vision Dysfunction current marketed and Age Related Vision Dysfunction emerging therapies
• Age Related Vision Dysfunction Market Dynamics: Age Related Vision Dysfunction market drivers and Age Related Vision Dysfunction market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Age Related Vision Dysfunction Unmet Needs, KOL's views, Analyst's views, Age Related Vision Dysfunction Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.